Oral PCSK9 inhibitor enlicitide lowers LDL cholesterol levels in phase 2 trial

Nature Cardiovascular Research 2026

View at publisher

Authors: Xiulin Koehler

DOI: 10.1038/s44161-026-00794-7

Cited by: 0

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Cholesterol and Lipid Metabolism Lipid metabolism and disorders